Those rates yielded an identical odds ratio of 2.53 when two different methods of statistical calculation were used, said Dr. Russell-Jones of the University of Surrey, Guildford, England.
Dr. Gale, in his closing remarks, referred to Diabetologia as the “epicenter of the storm.” As a result, “many members of the medical community and the public have been confused, and in some cases angry. I think this has been one of the most difficult, confusing, emotive, and controversial issues I have ever had to deal with.”
Acknowledging that he had received some criticism for publishing the articles in the first place, Dr. Gale said he has no regrets, noting, “The answer to the question may well be negative, but the question has to be asked.”
Dr. Johnson declared he had participated as a speaker for Eli Lilly & Co. Dr. Gale, Dr. Smith, and Dr. Currie stated they had no conflicts of interest. Both Dr. Skyler and Dr. Russell-Jones declared financial relationships with other diabetes-related companies in addition to the ones they were representing at the symposium.
On Sept. 29, Sanofi-Aventis announced the launch of a research program to investigate whether there is a relationship between cancer and insulin use, including the analogues (http://en.sanofi-aventis.com/binaries/20090929_easd_lantus_en_tcm28-26400.pdf
Headlines suggesting that glargine causes cancer are 'unsubstantiated, unwarranted, and unproven.'
Source Dr. Skyler